Abstract
Significant advances in the pharmacological prophylaxis of venous thromboembolism have occurred since warfarin and unfractionated heparin were introduced for this indication nearly 60 years ago. Despite these advances, coumarin derivatives such as warfarin remain the only orally active anticoagulants available for prophylaxis in venous thromboembolism. Although administered orally, coumarin derivatives are not convenient to use, because they have narrow therapeutic indexes and require routine coagulation monitoring and dose adjustment. This is inconvenient for patients and physicians and costly for the healthcare system. Low-molecular-weight heparins, which are administered in fixed or weight-adjusted doses and do not require monitoring, are widely used for the prevention of venous thromboembolism in patients in both the hospital and the outpatient setting. However, these drugs must be given subcutaneously, which can be difficult for outpatients and resource-intensive for in-hospital use. Likewise, fondaparinux, the synthetic pentasaccharide, must be administered subcutaneously. Consequently, there remains a need for new orally active anticoagulants that can be given in fixed doses and do not have a narrow therapeutic index, so that coagulation monitoring is unnecessary. Because such agents would be more convenient for patients and physicians, they would probably expand the use of prophylaxis in venous thromboembolism in those at risk, and would simplify treatment of patients with established venous thromboembolism.
Similar content being viewed by others
References
Bick RL, Fareed J. Current status of thrombosis: a multi-disciplinary medical issue and major American health problem: beyond the year 2000. Clin Appl Thromb Hemost 1997; 3 Suppl. 1: 1S–5S
Girard P, Musset D, Parent F, et al. High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest 1999; 116 (Pt 4): 903–8
Lindblad B, Eriksson A, Bergqvist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988. Br J Surg 1991; 78 (Pt 7): 849–52
Hansson PO, Welin L, Tibblin G, et al. Deep vein thrombosis and pulmonary embolism in the general population. ‘The Study of Men Born in 1913’. Arch Intern Med 1997; 157 (Pt 15): 1665–70
Bergqvist D, Lindblad B. A 30-year survey of pulmonary embolism verified at autopsy: an analysis of 1274 surgical patients. Br J Surg 1985; 72 (Pt 2): 105–8
Bergqvist D, Jendteg S, Johansen L, et al. Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden. Arch Intern Med1997; 126 (Pt 6): 454–7
Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107 (23 Suppl. 1): I9–16
Geerts WH, Heit JA, Lagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119: 132S–75S
Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals from the Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation 1996; 93 (Pt 12): 2212–45
Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998; 114(5 Suppl.): 561S–78S
Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119 (1 Suppl.): 8S–21S
Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001; 119 (1 Suppl.): 22S–38S
Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119(1 Suppl.): 108S–21S
Nichols WL, Bowie EJ. Standardization of the prothrombin time for monitoring orally administered anticoagulant therapy with use of the international normalized ratio system. Mayo Clin Proc 1993; 68 (Pt 9): 897–8
Hirsh J. Heparin. N Engl J Med 1991; 324 (Pt 22): 1565–74
Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119 (1 Suppl.): 64S–94S
Hirsh J, van Aken WG, Gallus AS, et al. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976; 53 (Pt 4): 691–5
Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332 (Pt 20): 1330–5
Hyers TM. Management of venous thromboembolism: past, present, and future. Arch Intern Med 2003; 163 (Pt 7): 759–68
Turpie AG, Eriksson BI, Bauer KA, et al. New pentasac-charide for the prophylaxis of venous thromboembolism: clinical studies. Chest 2003; 124 (Pt 6): 371S–8S
Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385–91
Adkins JC, Wilde MI. Lepirudin: a review of its potential place in the management of thrombotic disorders. BioDrugs 1998; 10: 227–55
Matheson AJ, Goa KL. Desirudin: a review of its use in the management of thrombotic disorders. Drugs 2000; 60: 679–700
Carswell CI, Plosker GL. Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Drugs 2002; 62: 841–70
McKeage K, Plosker GL. Argatroban. Drugs 2001; 61: 515–22
Stratton MA, Anderson FA, Bussey HI, et al. Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients. Arch Intern Med 2000; 160 (Pt 3): 334–40
Hull RD, Pineo GF, Stein PD, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systemic review. Arch Intern Med 2001; 161 (Pt 16): 1952–60
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ansell, J., Bergqvist, D. Current Options in the Prevention of Thromboembolic Disease. Drugs 64 (Suppl 1), 1–5 (2004). https://doi.org/10.2165/00003495-200464001-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200464001-00002